Licensing status

Publication and contact information


Ovarian cancer

ATPase class VI type 11B (ATP11B)

Mouse and cell culture studies suggest inhibiting ATP11B could help circumvent resistance to platinum chemotherapy in ovarian cancer. In a genomic analysis of a panel of ovarian cancer cell lines, cisplatin-resistant cells had greater ATP11B expression than cisplatin-sensitive lines. In a cisplatin-resistant ovarian cancer cell line, liposome-mediated delivery of ATP11B-targeted small interfering RNA increased cisplatin sensitivity compared with delivery of control siRNA. In multiple mouse xenograft models for cisplatin-resistant human ovarian cancer, cisplatin plus liposome-mediated delivery of ATP11B-targeted siRNA decreased tumor growth compared with cisplatin plus delivery of control siRNA. Next steps include further exploring the mechanisms underlying resistance to platinum chemotherapy.

SciBX 6(16); doi:10.1038/scibx.2013.387
Published online April 25, 2013

Patent application filed covering liposome-based siRNA delivery system; available for licensing from The University of Texas MD Anderson Cancer Center's Office of Technology Commercialization

Moreno-Smith, M. et al. J. Clin. Invest.; published online April 15, 2013;
Contact: Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, Texas